Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 30

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 30
---
| ● | not                                                                                                                     
 being required to comply with the requirement of auditor attestation of our internal controls over financial reporting; |

| ● | not                                                                                                                                    
 being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory 
 audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial         
 statements;                                                                                                                            |

| ● | reduced                                                      
 disclosure obligations regarding executive compensation; and |

| ● | not                                                                                                                                   
 being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments 
 not previously approved.                                                                                                              |

An emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act to comply with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting companies. We are also a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies. We will remain a smaller reporting company until the end of the fiscal year in which (1) we have a public common equity float of more than $250 million, or (2) we have annual revenues for the most recently completed fiscal year of more than $100 million and a public common equity float or public float of more than $700 million. We also would not be eligible for status as a smaller reporting company if we become an investment company, an asset-backed issuer or a majority-owned subsidiary of a parent company that is not a smaller reporting company. We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different from what you might receive from other public reporting companies in which you hold equity interests.

<div align='center'>S-17</div>

The Offering Common stock offered by us:Shares of our common stock having an aggregate offering price of $1,397,532.